# Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

Study · id `cardio:ct-nct03797001` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03797001](<https://clinicaltrials.gov/study/NCT03797001>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03797001

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT03797001. Randomized; quadruple masking; primary purpose treatment. Start 2019-01-04 (actual); primary completion 2024-07-22 (actual). Results posted on 2025-08-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT03797001, source copy `cardio:ctgov-nct03797001-2025-08-06`, retrieved 2026-10-26)
- Started: 2019-01-04 (actual) (ClinicalTrials.gov record NCT03797001, source copy `cardio:ctgov-nct03797001-2025-08-06`, retrieved 2026-10-26)
- Primary completion: 2024-07-22 (actual) (ClinicalTrials.gov record NCT03797001, source copy `cardio:ctgov-nct03797001-2025-08-06`, retrieved 2026-10-26)
- Completion: 2024-07-22 (actual) (ClinicalTrials.gov record NCT03797001, source copy `cardio:ctgov-nct03797001-2025-08-06`, retrieved 2026-10-26)
- Results first posted: 2025-08-06 (ClinicalTrials.gov record NCT03797001, source copy `cardio:ctgov-nct03797001-2025-08-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03797001, source copy `cardio:ctgov-nct03797001-2025-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03797001-2025-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
- Acronym: REDHART2
- Condition: Heart Failure, Systolic
- Condition: Inflammation
- Intervention (Drug): Anakinra
- Intervention (Drug): Placebo
- Lead sponsor: Virginia Commonwealth University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: Virginia Commonwealth University (`cardio:org-virginia-commonwealth-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra (`cardio:pubmed-41431894`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Interleukin-1 Receptor Antagonist Levels in Patients With Heart Failure and Reduced Ejection Fraction Treated With Anakinra (`cardio:pubmed-42455969`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: bca32309c3efec49476422627caf9c4e1cbaaad48471566a6d2bb481fca59f35
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
